Andrew D. Seidman, MD, and Richard G. Gray, MA, MSc, on Long-Term Aromatase Inhibitor Therapy
2018 San Antonio Breast Cancer SymposiumAndrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Richard G. Gray, MA, MSc, of the University of Oxford, discuss a meta-analysis of individual patient data from 12 randomized trials including 24,912 women on the effects—in terms of recurrence and cause-specific mortality—of prolonging adjuvant aromatase inhibitor therapy beyond 5 years (Abstract GS3-03).
Related Videos
Laura S. Dominici, MD, on Young Women With Breast Cancer: Local Therapy and Quality of Life
Laura S. Dominici, MD, of the Dana-Farber Cancer Institute, discusses the lower quality-of-life scores seen after unilateral or bilateral mastectomy compared with breast-conserving...
François-Clément Bidard, MD, PhD, on Metastatic Breast Cancer: Using Circulating Tumor Cells to Direct Treatment
François-Clément Bidard, MD, PhD, of the Institut Curie and the University of Versailles, discusses phase III study findings on the clinical utility of circulating tumor cell count...
Dejan Juric, MD, on Advanced Breast Cancer: Results From the SOLAR-1 Trial
Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of...
Roberto A. Leon-Ferre, MD, on Decreasing Hot Flashes: Results From an ACCRU Trial
Roberto A. Leon-Ferre, MD, of the Mayo Clinic, discusses study findings on the effectiveness of oxybutynin in decreasing the frequency and severity of hot flashes (Abstract GS6-01)...
Roisin M. Connolly, MD, on Breast Cancer Treatment Advances in 2018: Expert Perspective
Roisin M. Connolly, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses clinical trials during the past year on studies on CDK and PI3K inhibitors in e...
